Oncology Clinical Trials in Newark, DE

As of June 2026, 59 paid clinical trials are recruiting for Oncology in Newark, Delaware. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

59 clinical trials for Oncology

·Clear filters·↓ Download CSV

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Daratumumab

67 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting

Apply to this trial

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

for Multiple Myeloma

Drug: Teclistamab

42 locations incl. Phoenix

Sponsor: European Myeloma Network B.V.

Sex: All·Age: 18+

Code: NCT05243797·Phase 3·Recruiting

Apply to this trial

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

for Advanced Cancer

14 locations incl. Scottsdale

Sponsor: Riboscience, LLC.

Sex: All·Age: 18+

Code: NCT05270213·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

for Non-Hodgkin Lymphoma

Drug: Epcoritamab

18 locations incl. Tucson

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05283720·Phase 2·Recruiting

Apply to this trial

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

for Renal Cell Carcinoma (RCC)

46 locations incl. Phoenix

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05176483·Phase 1·Recruiting

Apply to this trial

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

for Breast Cancer, NOS

347 locations incl. Fairbanks

Sponsor: Eastern Cooperative Oncology Group

Sex: All·Age: 18 - 39

Code: NCT05108298·Recruiting

Apply to this trial

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

for Malignant Solid Neoplasm

843 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04871542·Recruiting

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

621 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

32 locations incl. Irvine

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

for Cancer

41 locations incl. Tucson

Sponsor: Tizona Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT04485013·Phase 1·Recruiting

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1150 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

for Prostate Adenocarcinoma

Drug: Apalutamide

345 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT04134260·Phase 3·Recruiting

Apply to this trial

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

for Colorectal Cancer

146 locations incl. Millville

Sponsor: Wake Forest University Health Sciences

Sex: All·Age: 60+

Code: NCT03998202·Recruiting

Apply to this trial

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

for Breast Cancer

451 locations incl. Fairbanks

Sponsor: Canadian Cancer Trials Group

Sex: Female·Age: 35+

Code: NCT03488693·Phase 3·Recruiting

Apply to this trial

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for Cancer, Metastatic

67 locations incl. Birmingham

Sponsor: Massive Bio, Inc.

Sex: All·Age: All ages

Code: NCT03452774·Recruiting

Apply to this trial

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

for Breast Cancer

130 locations incl. Birmingham

Sponsor: Agendia

Sex: All·Age: 18+

Code: NCT03053193·Recruiting

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

676 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting

Apply to this trial

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

for Hematopoietic and Lymphatic System Neoplasm

140 locations incl. Birmingham

Sponsor: National Cancer Institute LAO

Sex: All·Age: 2 Months+

Code: NCT02474160·Recruiting

Apply to this trial

Conditions in Oncology (Newark, DE)

Non-small cell lung cancer (NSCLC)· 12 Breast cancer· 11 Solid tumor· 9 Multiple myeloma· 5 Non-Hodgkin lymphoma· 5 Cancer (any)· 5 Colorectal cancer· 4 Ovarian cancer· 4 Melanoma· 4 Prostate cancer· 3 Chronic lymphocytic leukemia (CLL)· 3 Mantle cell lymphoma· 3 Head and neck cancer· 3 Metastatic breast cancer· 2 Gastroesophageal junction cancer· 2 Endometrial cancer· 2 Myelofibrosis· 2 Follicular lymphoma· 2 Small lymphocytic lymphoma· 2 Hematologic malignancy· 2 Triple-negative breast cancer· 1 HER2-positive breast cancer· 1 HER2-negative breast cancer· 1 Lung cancer· 1 Small cell lung cancer· 1 Metastatic colorectal cancer· 1 Rectal cancer· 1 Gastric cancer· 1 Esophageal cancer· 1 Liver cancer· 1 Biliary tract cancer· 1 Metastatic prostate cancer· 1 Bladder cancer· 1 Kidney cancer· 1 Glioblastoma· 1 Leukemia (other)· 1 Myelodysplastic syndromes (MDS)· 1 Myeloproliferative neoplasm· 1 Diffuse large B-cell lymphoma (DLBCL)· 1 Marginal zone lymphoma· 1 Burkitt lymphoma· 1 Neuroendocrine tumors· 1